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AbstrAct
Objective To examine the long-term predictive value of 
28 biomarkers for subsequent non-ischaemic congestive 
heart failure (CHF) and separately for other cardiovascular 
outcomes (myocardial infarction (MI) and stroke).
Methods The Caerphilly Prospective Study recruited 
2171 men aged 55–69 years from the general population 
in 1989–1993; men were screened for evidence of 
cardiovascular disease (CVD) and followed for clinical 
cardiovascular events. Fasting blood samples were stored 
at −70°C until assayed for novel biomarkers in 2010–
2013. A competing risks proportional hazards regression 
analysis was used to estimate subhazard ratios (SHRs) for 
each biomarker for each cardiovascular outcome.
Results During follow-up (average 13 years), only new, 
initial events were evaluated in the whole cohort: 584 
MIs, 313 strokes and 261 episodes of CHF (not associated 
with acute MI). In a subcohort of men who had no clinical 
history or evidence of CVD at baseline examination 
(n=1279) those in the top third of the distributions of 
troponin and B-type natriuretic peptide (BNP) showed a 
threefold increase in risk for subsequent CHF as a first 
event after adjustment for all conventional risk factors 
(SHRs 3.37, 95% CI 1.39 to 8.14 and 3.23, 95% CI 1.45 to 
7.23), respectively, in contrast to moderate elevations in 
risk for acute MI (troponin SHR 1.63, 95% CI 1.10 to 2.41) 
and for stroke (BNP SHR 1.75 95% CI 1.06 to 2.88).
Conclusion Troponin and BNP could be considered 
as potentially useful screening tools to detect subjects 
without prior CVD at increased risk of developing CHF in 
subsequent years in addition to having lesser roles for 
predicting subsequent MI (troponin) or stroke (BNP).
IntROduCtIOn
Cardiovascular diseases (CVDs) are the 
most important cause of death worldwide, 
projected to account for 24% of deaths 
by 2030 compared with 12% for cancers.1 
However, the increase in CVDs is occurring 
in low-income and middle-income countries, 
while decreasing in high-income countries.2 
Ischaemic heart disease (IHD) is the most 
common manifestation of CVD in high-income 
countries, while stroke and congestive 
heart failure (CHF) tend to predominate in 
many low-income and middle-income coun-
tries.3 Primary preventive measures in the 
general population resulting in lower levels 
of smoking, hypertension and serum choles-
terol appear to account for more than 50% 
of the decline in mortality from IHD and 
stroke in several high-income countries,4 
Key questions
What is already known about this subject?
 ► Chronic heart failure is a leading cause of mortality 
and morbidity and certain markers such as B-type 
natriuretic peptide (BNP) have been shown to help 
predict subsequent heart failure in subjects without 
a history of prior cardiovascular disease (CVD).
 ► Troponin levels have been investigated as 
a predictor of subsequent CVD risk and have been 
suggested to improve risk prediction when added 
to established risk models.
What does this study add?
 ► We have examined the relationship between 
separate first CVD events (acute myocardial 
infaction (MI), stroke and chronic congestive heart 
failure) in a cohort of men with no history or clinical 
evidence of prior CVD.
 ► We have examined both the frequency of the 
individual CVD events and also the utility of risk 
prediction models for each type of CVD event 
that included troponin and BNP in addition to 
established risk factors (also lipoprotein-a for acute 
MI).
How might this impact on clinical practice?
 ► Our study suggests that both BNP and troponin 
could usefully help predict subsequent chronic 
CHF in subjects with no prior evidence of CVD. 
In our data, troponin and BNP appear to have 
lesser roles in predicting acute MI and stroke, but 
these findings should be investigated in larger 
collaborative studies.
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although adverse trends are occurring worldwide in 
levels of obesity and diabetes,3 which are established risk 
factors for CHF.5 6 CHF is considerably under-reported 
as a cause of death as coding guidelines in the Interna-
tional Classification of Diseases discourage the recording 
of heart failure as an underlying cause of death,7 particu-
larly if other conditions are present such as IHD or (less 
commonly) hypertension. Evidence from hospital admis-
sions, however, suggests a steep rise in the prevalence of 
CHF in high-income countries.8 9 A meta-analysis of 26 
studies showed CHF to be an important risk factor for 
subsequent stroke.10
There is increasing evidence that coagulation and 
inflammatory factors play an important role in the patho-
genesis of CVDs, which appear to be largely initiated and 
progressed by atherothrombotic mechanisms.11 The role 
of such biomarkers in prediction of CHF has been less 
studied, but epidemiological studies have suggested a 
role for inflammatory cytokines with the development 
of CHF.12 Cardiac peptides have become established in 
clinical practice in the diagnosis and treatment of CHF,13 
and several epidemiological studies14 have suggested 
B-type natriuretic peptide (BNP), or its inactive N-ter-
minal fragment NT-pro BNP, to be of potential use in 
risk assessment for subsequent CHF in the general popu-
lation. We have previously investigated 28 conventional 
and novel markers representing several pathogenic path-
ways in relation to CVD and non-CVD mortality.15 We 
now examine if these markers have predictive value for 
CHF, acute myocardial infarction (MI) and stroke events 
(fatal and non-fatal) in the Caerphilly Prospective Study 
(CaPS), a population-based cohort of men examined in 
1989–1993.
MetHOds
study population
CaPS was established in 1979 when men from the general 
population of the South Wales town of Caerphilly and its 
surrounding villages were recruited; 89% of the eligible 
population was examined, and the cohort, which has 
previously been characterised,16 was re-examined at 
approximately 5 yearly intervals. A detailed medical and 
lifestyle history was obtained, the London School of 
Hygiene & Tropical Medicine (LSHTM) chest pain ques-
tionnaire was administered, a full resting 12-lead ECG 
was recorded and height, weight and blood pressure were 
measured as described previously.17 ECGs were coded 
by two experienced coders according to the Minnesota 
coding scheme.
This report is based on the second follow-up examina-
tion of the men (phase 3) in the period 1989–1993 when 
the men were predominantly aged 55–69 years. Of the 
2171 men examined, a fasting blood sample was obtained 
subsequently from 1911 (88%) men.
A subsample of men who had no evidence of existing 
ischaemia, angina, severe chest pain (from the LSHTM 
questionnaire) or history of stroke at the baseline 
examination were selected to examine the first subse-
quent cardiovascular events in this cohort as defined 
below. Men with any evidence of ECG ischaemia using 
the Whitehall criteria for ECG ischaemia (Q-waves, ST 
depression, T wave inversion and left bundle branch 
block) were excluded from this subsample. All men gave 
written informed consent.
Blood collection, storage and analysis
At a separate appointment, shortly after the clinical exam-
ination, a venous blood sample was collected from each 
man after an overnight fast. Fresh samples were used to 
measure acute phase reactants and routine lipids and 
routine biochemistry as described previously.17 Other 
aliquots were taken, and plasma or serum were separated 
within 1 hour and stored at −20°C for up to 6 hours and 
then at −70°C until laboratory analysis in 2010–2013.
Biomarker assays
Assays for high-sensitivity troponin, BNP, C reactive 
protein (CRP), growth differentiation factor-15, cysta-
tin-C, creatinine, ferritin and lipoprotein-a (Lp-a) were 
performed in the BiomarCaRE laboratory as described 
elsewhere.18 Vascular cell adhesion molecule-1, E-se-
lectin, interleukin-6 (IL-6), pregnancy-associated plasma 
protein-A, retinol binding protein-4, fetuin-A and IL-6 
receptor were assayed using commercial ELISAs, and 
vitamin B6 was measured using high-performance liquid 
chromatography. Coefficients of variation for assays in 
our panel of biomarkers for blindly presented duplicate 
aliquots varied from 1% to 27% as reported previously.15
Follow-up
Fatal events
The men have been followed for mortality through flag-
ging by the Health and Social Care Information Centre 
with follow-up until 28 February 2012. The underlying 
cause of death coded from the death certificate was 
used. MI/IHD codes were International Classification of 
Diseases, 9th revision (ICD-9) 410–414, ICD, 10th revi-
sion (ICD-10) I20–I25, stroke codes were ICD-9 430–438 
and ICD-10 I60–I69 and CHF codes were ICD-9 428 and 
ICD-10 I50.
Non-fatal events
We tracked non-fatal events for men in the cohort who 
gave written consent to link their data to their hospital 
records in the Hospital Episode Statistics (HES) system as 
described previously.17 In the current report, all hospital 
admissions for Wales from January 1998 to 28 February 
2012 were examined for possible disease episodes. We 
used the identical ICD-10 codes as for deaths with the 
addition of I46 for IHD, G45 and G46 for stroke and 
I11 and I13 for CHF.
Electronic health records from primary care were used 
to validate diagnoses obtained from HES. These are avail-
able for all residents in the Caerphilly area and contain 
scanned copies of hospital discharge letters dating 
from the late 1990s. Subjects were also re-examined in 
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1994–1998 and in 2002–2005 when detailed question-
naires were used to capture details of new clinical events.
Prior to the year 2000, an MI/IHD or stroke event was 
validated by an independent medical committee using 
hospital notes and primary care records. Stroke was based 
on clinical history and CT as described previously.16
After the year 2000, a new medical committee (LH, 
YB-S and AB) reviewed hospital admissions from 1998 to 
2012 and summary electronic GP records predating these 
hospital admissions. A diagnosis of acute MI was based 
on the consultant discharge letter, diagnostic troponin 
values and evidence of ischaemia on ECG as in the Third 
Universal Definition of Myocardial Infarction criteria.19 
Stroke was classified as transient ischaemic attack, isch-
aemic stroke, intracerebral haemorrhagic stroke or stroke 
of uncertain subtype by the committee using clinical 
records and CT, but possible subarachnoid haemorrhage 
events were not included. Possible CHF events were diag-
nosed according to the Framingham criteria20 supported 
by echocardiography when available and/or a diagnosis 
made by a consultant cardiologist. Acute CHF episodes of 
limited duration (<24 hours) following MI were excluded 
from the validated CHF cases. In the subsample of men 
with no evidence of prior IHD/stroke, as defined above, 
events defined as first CHF events were considered to be 
non-ischaemic.
statistical methods
Analysis is based on 1112 men with no history of CVD who 
provided fasting blood samples and had complete data 
on all relevant covariates. The majority of biomarkers 
showed skewed distributions, and small numbers of 
men had results below a lower limit of detection for 
some biomarker assays. Biomarker results were there-
fore summarised using median and IQRs and compared 
between subgroups using the Mann-Whitney U test. 
Biomarker distributions were divided into thirds by 
sample tertiles for further analysis.
A competing risk formulation of Cox’s proportional 
hazards regression model was used to estimate subhazard 
ratios (SHRs) for each CVD outcome with other outcomes 
treated as competing risks.21 This approach models 
cumulative incidence functions rather than cause-spe-
cific hazard functions.22 Tests for linear trend in the 
SHRs across the thirds of each biomarker were obtained 
together with tests for deviation from linearity across the 
thirds. A time-dependent covariate test was used to inves-
tigate the subhazard proportionality assumption that 
specifies that there is no change in the SHRs with time. A 
significant interaction between the trend in a categorised 
biomarker and time in the Cox model provided evidence 
of failure of the proportional subhazards assumption.
Harrell’s C statistic23 was calculated as a measure of 
the predictive ability of regression models that included 
troponin and BNP separately and together in addition to 
conventional risk factors.
To reduce the risk of type 1 errors arising in the multiple 
testing, the 1% significance level was employed for all 
tests. Analyses were performed using SPSS version 20 and 
Stata release 12.
Results
The mean period of follow-up for the 2171 men was 
13.0 years (range 0.01–22.5 years) with a total of 28 312 
person-years. The numbers of men in various subgroups 
analysed in this report are listed in online supplementary 
table 1.
Figure 1A shows the number of outcome events in all 
subjects: 584 acute MI/IHD events (at an average of 9.3 
years of follow-up), 313 stroke events (at an average of 9.8 
years of follow-up) and 261 CHF events (at an average of 
12.0 years of follow-up). However, these events occurred 
in 900 men as many men had more than one type of 
outcome event. For example, of the 261 men who expe-
rienced a CHF event, 148 (123+25) also had acute MI/
IHD and 54 (29+25) a stroke; in 61 of these 148 men, 
CHF was the first event. When a CHF event occurred 
during the same day as an MI/IHD or stroke event, the 
latter was counted as the first event. In the whole cohort, 
Figure 1 Outcome events in the Caerphilly Prospective 
Study (CaPS) during 13 years of follow-up. (A) All men (n = 
2171), (B) men without pre-existing CVD (n=1279).
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which included men with prior CVD, 84 men experi-
enced a CHF event without any MI/IHD or stroke event. 
Therefore, of 900 men with any CVD event, 145 (16%) 
had a CHF event first. However, as our cohort did not 
exclude men with evidence of prior CVD, as defined in 
the methods section, 80 had such evidence indicating 
that 55% of these 145 men who experienced a CHF event 
first had prior CVD.
In the light of this observation, we investigated the 
subsample of men (n=1279) who had no evidence of prior 
CVD, and we categorised first CHF events as non-isch-
aemic. Figure 1B shows that 114 CHF events occurred in 
this subcohort, and there were also 259 MI/IHD events 
and 178 strokes that occurred in a total of 438 men.
The numbers of first events were as follows: 217 for 
acute MI/IHD, 158 for stroke and 63 for CHF, for a total 
of 438 first CVD events. In these, 438 men 63 (14%) had 
a CHF event first. Therefore, in men with no evidence of 
CVD at baseline, 55% (63/114) of CHF events preceded 
other cardiovascular outcomes or occurred as the only 
type of outcome during the follow-up period.
Table 1 shows the median value of each of the 
biomarkers grouped by pathogenic pathway in men with 
no event during follow-up, those with a first MI/IHD 
event, those with a first stroke and in those with a first 
CHF event. Only 1176 fasting men without evidence of 
prior CVD at baseline were included in this analysis.
Men who experienced a first MI/IHD or a first CHF 
event (but not men who experienced a first stroke event) 
showed significantly higher levels of troponin than those 
men with no events. BNP levels were significantly higher 
in men with a first stroke and markedly and significantly 
higher in men with a first CHF event.
One inflammatory marker, CRP, and three acute phase 
proteins, white blood cell count, viscosity and fibrinogen 
tended to show higher levels in men with all types of new 
CVD events, but only men with new first MI/IHD events 
(the most frequent CVD outcome) showed significant 
differences from men with no events. Lipid levels, total 
cholesterol, triglycerides and Lp-a were notably higher 
in men with new MI/IHD. Glucose levels were higher in 
men with all types of new CVD events compared with men 
with no events, although the result attained significance 
only for stroke outcome. Alkaline phosphatase showed 
significantly raised levels in new stroke subjects, while 
aspartate transaminase levels were significantly lower in 
this group.
In table 2, the distributions of each biomarker have 
been divided into thirds and crude (adjusted for age 
only) and fully adjusted SHRs have been calculated. 
Adjustment was made for the following conventional risk 
factors: age, smoking, diabetes, systolic blood pressure, 
total cholesterol, total triglycerides, body mass index and 
male/female family history of premature CHD.
In the top third of the distributions of troponin and 
BNP, the highest values were for CHF (SHRs 3.37, 95% CI 
1.39 to 8.14 and 3.23, 95% CI 1.45 to 7.23), respectively, 
adjusted for all conventional risk factors.
For acute MI/IHD, the SHR for troponin was only 
moderately elevated in the top third of the distribution 
(SHR 1.63, 95% CI 1.10 to 2.41). For stroke, the SHR 
for third of the distribution was not raised for troponin 
but was significantly raised for BNP (SHR 1.75 95% CI 
1.06 to 2.88). Of the remaining biomarkers, only the 
lipids total cholesterol and Lp-a and the liver enzyme 
aspartate transaminase showed significant associations 
with either acute MI/IHD or stroke (for acute MI/IHD 
the top third SHR was 2.48 (95% CI 1.63 to 3.77) for 
total cholesterol and 1.84 (95% CI 1.26 to 2.69) for Lp-a; 
for aspartate transaminase, the respective SHRs were 
0.68 (95% CI 0.46 to 0.99) for acute MI/IHD and 0.63 
(95% CI 0.41 to 0.96) for stroke.
None of the significant associations between biomarkers 
and CVD risk showed non-linearity in the relationship. 
Tests of interaction with time showed no evidence that 
the strength of the significant associations changed with 
length of follow-up.
Table 3 provides a summary of the main results in 
which the adjusted SHRs have been calculated per third 
of each biomarker distribution (a summary figure across 
the distribution of each biomarker) for the individual 
CVD outcomes. Results significant at the 1% level of 
statistical significance are shown in bold type. Adjustment 
was made for the same conventional risk factors as listed 
for table 2.
SHRs for non-ischaemic CHF showed strong significant 
associations with troponin and BNP, while lesser associ-
ations were shown for troponin in the case of MI/IHD 
events and for BNP in the case of stroke events. Total 
cholesterol and Lp-a showed associations for MI/IHD 
events only (with SHRs larger than that for troponin). 
No other biomarker showed a statistically significant SHR 
with each of these individual CVD outcomes in these men 
with no evidence of prior CVD.
Thus, for CHF, there are strong associations with 
troponin and BNP and weaker associations between these 
biomarkers and MI/IHD and stroke. The strongest asso-
ciations for MI/IHD were with total cholesterol and Lp-a.
For the CHF outcome, we tested the effect of adjusting 
for all conventional risk factors and troponin and BNP 
simultaneously; the SHR for troponin was slightly reduced 
(from 1.84 to 1.64) with no change for BNP. For MI/IHD, 
we examined the effect of adjusting for total cholesterol 
and Lp-a together with conventional risk factors (other 
than total cholesterol). The SHR for total cholesterol was 
slightly reduced (1.55 to 1.48), but the SHR for Lp-a was 
unchanged.
Similarly, we calculated Harrell’s C statistic with and 
without the inclusion of both troponin and BNP. Using 
the competing risks model for MI/IHD including the 
conventional risk factors and Lp(a), the inclusion 
of troponin after the addition of BNP increased the 
value of the C statistic from 0.678 to 0.688, whereas 
the addition of BNP to a model that included troponin 
produced only a modest change from 0.685 to 0.686. For 
CHF, both troponin and BNP appeared to contribute to 
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risk prediction: the addition of troponin to the model 
that included the conentional risk factors along with 
BNP increased the C statistic from 0.767 to 0.777, while 
the addition of BNP to the troponin model increased 
the C statistic from 0.745 to 0.775. However, none of 
these changes attained statistical significance (online 
supplementary table 2), possibly because the number 
of outcome events, particularly for CHF, was small. C 
statistics were not calculated for stroke since none of 
the biomarkers was significant for this endpoint.
dIsCussIOn
In this report, we have examined the relative contri-
butions of a panel of biomarkers to the prediction of 
three major cardiovascular events, fatal and non-fatal, 
in a general population of men aged 55–69 years in 
the early 1990s. During an average follow-up period 
of 13 years, many men experienced more than one 
type of cardiovascular event, but acute MI/IHD events 
predominated, followed by stroke and (chronic) CHF 
(figure 1A). Acute heart failure associated with acute 
MI/IHD was excluded from the CHF events, as defined 
in our study. As the general population included men 
with a prior history of CVD or clinical evidence of 
this from a resting ECG, we defined a subcohort that 
excluded these men (figure 1B). Among the 458 men 
in this subcohort who experienced a first event, acute 
MI/IHD events predominated (50%) with fewer strokes 
(36%) and CHF events (14%). These CHF events were 
categorised by the authors as non-ischaemic in origin.24 
However, in the full cohort, it was clear that prior CVD 
preceded chronic CHF in a high proportion of cases; 
some 55% having a history of MI or stroke prior to the 
baseline examination at phase 3, symptoms suggestive 
of IHD or resting ECG ischaemia without symptoms. 
The latter comprised a group of men without symp-
toms of CVD at baseline and without a prior CVD event. 
Therefore, a significant number of men who went on to 
develop CHF would have been unrecognised as being 
at risk at baseline.
A major objective of our study was to examine the 
predictive value of our panel of 28 biomarkers for acute 
MI/IHD, stroke and non-ischaemic CHF. Following 
adjustment for all classical risk factors, high-sensitivity 
troponin and the natriuretic peptide BNP showed the 
strongest predictive values for non-ischaemic CHF, 
and troponin showed a weaker association with acute 
MI/IHD as previously noted for CHF (not necessarily 
defined as non-ischaemic) in the Atherosclerosis Risk in 
Communities (ARIC) and Cardiovascular Health Study 
cohorts.25 26 Furthermore, we found that both BNP 
and troponin contributed independently to the risk of 
CHF but only troponin and, more strongly, total choles-
terol and Lp-a (again acting largely independently), 
predicted risk of acute MI/IHD. Nambi et al27 from the 
ARIC study reported that troponin and BNP together 
have significant value in the prediction of subsequent B
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CHF, which was confirmed in our present report in 
subjects without prior CVD. Unsurprisingly, we found 
that baseline levels of BNP predicted stroke risk but not 
acute MI/IHD.
In a major trial of more than 17 000 men and women 
with low-density lipoprotein cholesterol levels less than 
3.4 mmol/L, baseline levels of high sensitivity troponin 
in the highest tertile were associated with a HR of 
2.2 (95% CI 1.6 to 3.1) for a first CVD event and 2.6 
(95% CI 1.8 to 3.8) for all-cause mortality.28 Compa-
rable figures for BNP were 1.9 (95% CI 1.4 to 2.7) for 
CVD and 1.5 (95% CI 1.0 to 2.0) for all-cause mortality. 
In a previous report, we found that troponin and BNP 
were strongly predictive of CVD mortality but not for 
non-CVD mortality, and we suggested that biomarkers 
should be examined for specific causes of mortality in 
cohort studies.15 With the exception of total cholesterol 
and Lp-a and fatal and non-fatal MI/IHD, none of the 
other panel of biomarkers, including several inflam-
matory markers, showed convincing associations with 
the individual cardiovascular outcomes in this subco-
hort of men. Although previous cohort studies13 and 
reviews29 30 have suggested a role for inflammatory 
biomarkers in the pathogenesis of CHF, we found no 
evidence of this in our long-term follow-up study of 
non-ischaemic CHF events. Differences in the defini-
tion of CHF events and the length of follow-up may 
account for these differences.
Table 3 Sub-hazard ratios (95% CI) for MI/IHD, stroke and congestive heart failure per third of each biomarker distribution in 
a competing risk model for 1112 fasting men with no CVD at entry and complete covariate data
Biomarker 
MI/IHD Stroke Congestive Heart failure
Sub-hazard ratio (95% CI) Sub-hazard ratio (95% CI) Sub-hazard ratio (95% CI)
Troponin 1.30 (1.07 to 1.59) 0.83 (0.64 to 1.06) 1.84 (1.21 to 2.80)
BNP 1.10 (0.91 to 1.33) 1.33 (1.04 to 1.70) 1.94 (1.26 to 2.97)
CRP 1.10 (0.90 to 1.35) 1.01 (0.80 to 1.28) 1.00 (0.71 to 1.41)
IL-6 0.94 (0.78 to 1.14) 1.14 (0.91 to  1.42) 0.84 (0.57 to 1.22)
IL-6 receptor 1.02 (0.84 to 1.23) 0.92 (0.72 to 1.16) 1.04 (0.74 to 1.47)
Cholesterol 1.55 (1.27 to 1.88) 0.89 (0.72 to 1.10) 1.13 (0.78 to 1.63)
Triglyceride 1.08 (0.88 to 1.33) 1.01 (0.81 to 1.25) 0.77 (0.54 to 1.10)
Lp-a 1.35 (1.12 to 1.63) 0.90 (0.71 to 1.13) 0.69 (0.45 to 1.04)
VCAM-1 0.90 (0.75 to 1.10) 1.05 (0.84 to 1.32) 1.28 (0.88 to 1.86)
E-selectin 0.88 (0.73 to 1.07) 1.17 (0.93 to  1.47) 1.16 (0.79 to 1.69)
Alkaline phosphatase 0.92 (0.76 to 1.11) 1.22  (0.98 to  1.51) 0.92 (0.65 to 1.33)
Aspartate transaminase 0.83 (0.69 to 1.00) 0.77  (0.61 to  0.98) 1.31 (0.91 to 1.84)
Alanine transaminase 0.96 (0.79 to 1.18) 0.99  (0.79 to  1.25) 1.00 (0.70 to 1.43)
Gamma-GT 0.89 (0.73 to 1.09) 1.00 (0.79 to 1.26) 0.98 (0.71 to 1.34)
Glutamate dehydrogenase 1.00 (0.78 to 1.32) 1.07  (0.77 to  1.49) 1.11 (0.66 to 1.85)
White cell count 1.20 (1.00 to 1.45) 1.20 (0.93 to 1.53) 1.13 (0.75 to 1.70)
Viscosity 1.12 (0.93 to 1.35) 1.13 (0.90 to 1.41) 1.21 (0.84 to 1.75)
Fibrinogen 1.16 (0.96 to 1.39) 1.11 (0.89 to 1.37) 0.95 (0.65 to 1.38)
Ferritin 0.94 (0.79 to 1.13) 1.02 (0.81 to  1.28) 1.33 (0.88 to 2.01)
GDF-15 0.95 (0.77 to 1.17) 0.94 (0.74 to 1.21) 1.08 (0.71 to 1.66)
PAPP-A 1.02 (0.84 to 1.23) 1.14 (0.91 to 1.44) 1.41 (1.00 to 1.97)
Cystatin 1.01 (0.83 to 1.23) 1.14 (0.90 to 1.45) 1.01 (0.66 to 1.53)
Creatinine 0.85 (0.70 to 1.02) 0.89 (0.71 to 1.12) 1.21 (0.80 to 1.82)
Glucose 1.09 (0.88 to 1.34) 1.12 (0.88 to 1.42) 1.07 (0.76 to 1.49)
RBP-4 0.93 (0.77 to 1.11) 0.84 (0.66 to 1.07) 0.82 (0.58 to 1.17)
Fetuin-A 1.03 (0.86 to 1.24) 1.11 (0.88 to 1.41) 1.31 (0.94 to 1.82)
Uric acid 0.94 (0.78 to 1.13) 1.04 (0.81 to 1.33) 1.19 (0.83 to 1.71)
Vitamin B6 1.00 (0.82 to 1.21) 0.96 (0.76 to 1.21) 1.12 (0.79 to 1.57)
Results in bold are significant (P<0.01).
Adjusted for covariates: age, smoking, diabetes, systolic blood pressure, total cholesterol, total triglycerides, body mass index and 
family history of premature CHD.
BNP, B-type natriuretic peptide; CHD, coronary heart disease; CRP, C reactive protein;  CVD,  cardiovascular disease; GDF-15, 
growth differentiation factor-15;  IHD, ischaemic heart disease; IL, interleukin; Lp-a, lipoprotein-a; MI, myocardial infarction; PAPP-A, 
pregnancy- associated plasma protein-A; RBP-4, retinol binding protein-4;  VCAM-1, vascular cell adhesion molecule-1. 
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strengths and limitations
The major strength of our study is that we have 
defined first events for acute MI/IHD, stroke and 
CHF in subjects without a history of symptomatic or 
clinical (ECG) evidence of prior CVD. Measurement 
of troponin, and more particularly of BNP, may be 
useful as a screening test in the middle-aged popula-
tion of men to detect those at higher risk of developing 
subsequent CHF. Limitations of our report are that 
the number of first events of CHF in our subcohort is 
small, statistical power is modest and our results are 
restricted to a specific population of men. We cannot 
exclude the possibility that ischaemia that did not 
result in clinical symptoms may have occurred during 
the follow-up period. However, in a sensitivity analysis, 
which excluded men with ECG evidence of ischaemia 
and atrial fibrillation at baseline resulting in a subco-
hort of men totalling 1642, SHRs for the top third of 
the distributions of troponin were reduced for CHF and 
acute MI/IHD outcomes: 1.98 (95% CI 1.02 to 3.98) 
and 1.40 (95% CI 1.00 to 1.97). Similarly, the SHR for 
the top third of the distribution of BNP was reduced in 
the case of CHF events: 2.43 (95% CI 1.27 to 4.66). This 
suggests that men with a history of severe chest pain 
and those with symptoms of angina of effort also have 
myocardial damage or ischaemia without evidence of 
this on a resting ECG. We conclude that:
a. In this cohort of men of average age 62 years followed 
for an average of 13 years acute MI/IHD events 
occurred twice as commonly as CHF events, with 
stroke events taking an intermediate rank.
b. In a subcohort of men without prior CVD, 55% of first 
CHF events during follow-up were not preceded by 
other cardiovascular outcomes or occurred as the only 
type of outcome.
c. Men without prior CVD in the top third of the 
distributions of troponin and BNP at baseline 
examination had a greater than threefold risk of 
experiencing a CHF event compared with men in the 
bottom third in contrast to 1.63 tmies therisk of MI 
for troponin and 1.75 times the risk of stroke for BNP.
d. Troponin and BNP could be considered as potentially 
useful screening tools to detect subjects without 
prior CVD at increased risk of developing CHF in 
subsequent years in addition to having lesser roles 
for predicting subsequent risk of MI for troponin and 
stroke for BNP.
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